Medical Technology

@xconomy.com 3 years ago

Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D

@xconomy.com 3 years ago

Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally

@xconomy.com 3 years ago

Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases

@xconomy.com 3 years ago

HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic

@xconomy.com 4 years ago

Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses

@xconomy.com 4 years ago

Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod

@xconomy.com 4 years ago

CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019

@xconomy.com 4 years ago

Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy

@xconomy.com 4 years ago

Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More

@xconomy.com 4 years ago

Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus

@xconomy.com 4 years ago

Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic

@xconomy.com 4 years ago

Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal

@xconomy.com 4 years ago

Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further

@xconomy.com 4 years ago

Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds